Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05196932 · ClinicalTrials.gov registry record
COVID Card Pilot Study to Detect Antibodies to SARS-CoV-2
A clinical trial, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- 56
- Enrollment target
NCT05196932: Completed study, sponsored by University of Maryland, Baltimore.
NCT05196932 is a clinical trial that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05196932 has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
Study Summary
This study aims to investigate the clinical performance characteristics of the novel point-of-care, semi-quantitative test for SARS-CoV-2 in the Emergency Department compared to the gold standard (ELISA).
Primary Outcome
To measure the diagnostic sensitivity, specificity, and accuracy compared to the gold standard central laboratory SARS-CoV-2 antibody test.
Interventions
- DEVICE Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2023-04-21 |
What the finished NCT05196932 record still lists
NCT05196932 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 56 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies is the first listed.
NCT05196932 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05196932 about?
NCT05196932 is a clinical study titled "COVID Card Pilot Study to Detect Antibodies to SARS-CoV-2". This study aims to investigate the clinical performance characteristics of the novel point-of-care, semi-quantitative test for SARS-CoV-2 in the Emergency Department compared to the gold standard (ELISA).
What is the current status of trial NCT05196932?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2022-08-31. Estimated completion is 2023-04-21.
What interventions are being tested in trial NCT05196932?
The interventions under investigation include: Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies (DEVICE).
Who is sponsoring clinical trial NCT05196932?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI